TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01992796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Description: 75 mg/per os/for 15 days
Study: NCT03415321

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Postpartum Mobile Support Application
Description: Women in the experimental group will use the Postpartum Mobile Support Application during six weeks after birth.~Women will be evaluated three times in total, one for the first day after birth, second for the seventh day after birth and the last for the sixth week after birth.~Short messages and calls will be remind of women's Postpartum Mobile Support Application use
Study: NCT00139152

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline, Sub-Cuteanous (SQ)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xolair
Description: Xolair, 0.016 mg/kg Immunoglobulions E (IgE) , SQ
Study: NCT04355754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventil - a gas flow divider
Description: Checking ventilation parameters set and obtained and clinical parameters while ventilating the patient and an artificial lung simultaneously, using inspiratory flow divider.
Study: NCT01866332

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Combination of manual therapy techniques, general exercises and specific exercises for spinal segmental stabilization. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). The treatment will be tailored to the patient presentation (i.e. pragmatic treatment).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy
Description: Combination of manual therapy techniques, general exercises and specific exercises for spinal segmental stabilization. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). The treatment will be tailored to the patient presentation (i.e. pragmatic treatment).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio Tex Gold ( Kinesiotaping )
Description: Kinesiotaping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the superficial back muscles (erector spinae muscles).
Study: NCT04515771

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PARTNER-MH
Description: The study intervention consisted of a 6-month, manualized, peer-led navigation program. It involved assessing and addressing patients' unmet social needs and barriers to care, delivery of peer support services, navigation to VA mental health services, and psychoeducation.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PARTNER-MH
Description: The study intervention consisted of a 6-month, manualized, peer-led navigation program. It involved assessing and addressing patients' unmet social needs and barriers to care, delivery of peer support services, navigation to VA mental health services, and psychoeducation.
Study: NCT03261648

Intervention type: OTHER
Intervention: State-Trait-Anxiety Inventory (Forme Y) questionnaire
Description: after admission in the emergency department, patient and his partner will completed STAI Y questionnaire.

Intervention type: OTHER
Intervention: State-Trait-Anxiety Inventory (Forme Y) questionnaire
Description: after admission in the emergency department, patient and his partner will completed STAI Y questionnaire.

Intervention type: OTHER
Intervention: pain level scale
Description: as usual caregiver will ask to the patient to evaluated his pain level with a scale of one to ten
Study: NCT00948246

Intervention type: DEVICE
Intervention: Easyband®
Description: The Easyband adjustable gastric band device is implanted laparoscopically around the top of the stomach to create a small pouch. Adjustments to increase or decrease the stoma size are made non-invasively by telemetric connection between an internal and external antenna.
Study: NCT03978936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Therapy Management (MTM) Video Telehealthcare
Description: MTM is an individualized approach to optimize medication use for improved patient outcomes and is designed to empower patients to take an active role in managing patients' medications thus, providing a favorable strategy for addressing adherence issues. Five core elements define MTM: complete medication therapy review (CMR), creation of a personal medication list (PML), development of a medication action plan (MAP), intervention and/or referral for drug therapy problems, and documentation and follow-up

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Adherence Self-Management (EAM)
Description: Participants will have a sensor which monitors their adherence to medication use

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Adherence Self-Management (EAM)
Description: Participants will have a sensor which monitors their adherence to medication use
Study: NCT02764385

Intervention type: OTHER
Group type: OTHER
Intervention: Teachable Moment Communication Process
Description: A clinician-focused intervention designed to guide an approach to discussing smoking cessation during routine primary care visits.

Intervention type: OTHER
Group type: OTHER
Intervention: AAC
Description: A system-based change to the EHR that allows for eReferral to the Quitline coupled with role and process changes for medical technical assistants

Intervention type: OTHER
Group type: OTHER
Intervention: AAC
Description: A system-based change to the EHR that allows for eReferral to the Quitline coupled with role and process changes for medical technical assistants
Study: NCT04291547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BALM
Description: An online Behavioural Activation programme for young people with mild to moderate low mood/depression. The programme comprises 10 treatment sessions lasting 30 to 45 minutes
Study: NCT00445081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclosporine A
Study: NCT02439697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Conversion from Aranesp® to NESP®

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Conversion from Aranesp® to NESP®

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Conversion from Aranesp® to NESP®
Study: NCT00520949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Augmentin (Amoxicillin-clavulanic)
Description: Amoxicillin-clavulanic acid 1 gram b.i.d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furoxone (furazolidone)
Description: furazolidone 200 mg b.i.d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebes (colloidal bismuth subcitrate)
Description: colloidal bismuth subcitrate 240 mg b.i.d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esso (esomeprazole)
Description: esomeprazole 40 mg b.i.d for 14 days
Study: NCT00202280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid 5mg, Vitamin B12 0.4mg and B6 50mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid 5mg, Vitamin B12 0.4mg and B6 50mg
Study: NCT01870349

Intervention type: PROCEDURE
Intervention: Gingival Crevicular Fluid Sampling
Description: Gingival crevicular fluids will be sampled from single implant restorations that have been in function for at least 6 months

Intervention type: PROCEDURE
Intervention: Gingival Crevicular Fluid Sampling
Description: Gingival crevicular fluids will be sampled from single implant restorations that have been in function for at least 6 months
Study: NCT02979977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 30-60 minutes after the recommended pre-medications, cetuximab will be administered intravenously at a dose of 400mg/m2 on cycle 1, day 1 of treatment (loading dose) and at a dose of 250mg/m2 every 7 days (+/- 1 day) thereafter. Alternatively, patients can be treated at a dose of 500mg/m2 every 14 days (+/- 2 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib
Description: Patients will take a single oral dose of afatinib each day at a dose of 30 mg. Afatinib dose will not be escalated beyond the 30 mg daily oral dose; dose reductions of afatinib can occur to manage treatment related adverse events.
Study: NCT04434482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP4297(senaparib)
Description: The dose levels will be escalated following a modified 3+3 dose escalation scheme.
Study: NCT01612351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Weekly carboplatin given intravenously for 6 weeks during induction chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Weekly paclitaxel given intravenously prior to carboplatin infusion for 6 weeks during induction chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Lapatinib (1000mg) taken by mouth once a day either one hour before or one hour after a meal for 6 weeks during induction chemotherapy. Participants deemed high risk following transoral surgery will additionally take lapatinib daily concurrently with their chemoradiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Weekly cisplatin given intravenously for 6 weeks concurrent with ipsilateral radiation. Alternative regimens may be substituted for cisplatin in patients who are not candidates for cisplatin at the discretion of the investigator. If carboplatin is used, a maximum of 125 mL/min must be used, as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin given once every 3 week cycle intravenously for 5-7 weeks concurrent with bilateral radiation and daily lapatinib. Alternative regimens may be substituted for cisplatin in patients who are not candidates for cisplatin at the discretion of the investigator. If carboplatin is used, a maximum of 125 mL/min must be used, as per standard of care.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ipsilateral Radiation
Description: After transoral surgery, subjects deemed medium risk will receive ipsilateral radiation as per standard of care 5 days/week for 6 weeks concurrent with weekly cisplatin.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Bilateral Radiation
Description: After transoral surgery, subjects deemed high risk will receive bilateral radiation as per standard of care 5 days/week for 5-7 weeks concurrent with cisplatin every 3 weeks and daily lapatinib.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transoral Surgery
Description: Transoral resection by robotic or microscopic approach, which will be at the discretion of the treating surgeon.
Study: NCT02152891

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHAP-EMS/CP@clinic
Description: Community Paramedicine program to assess cardiovascular, diabetes, and fall risk; discuss lifestyle changes and goals; and refer to appropriate resources.
Study: NCT03246971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wafermine™ 50 mg
Description: Administered as needed for 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wafermine™ 75 mg
Description: Administered as needed for 12 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Administered as needed for 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wafermine™ 25 mg
Description: Administered as needed for 12 hours
Study: NCT02226393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged exposure
Description: The PE treatment includes 12-15 60 minutes' sessions. The 2 main components of the treatment are psychoeducation about common reactions to trauma and in-vivo exposures (gradual exposure to trauma related situations and objects) and repeated recounting of the traumatic memory, Trauma memory recounting and in-vivo exposures are conducted during several successive sessions so the child learns that the exposures themselves pose no real harm to him, indicating that when one confronts what one is afraid of it becomes easier to manage.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Child-parent Play Therapy
Description: Is consisted of 12-15 weekly 60 minute sessions of parent-child centered therapy it focus on establishing a trusting, empowering, and validating therapeutic relationship. Participants are allowed to choose when, how, and whether or not to address their trauma memory. Therapists provide active listening, empathy,and encouragement to talk about feelings and express belief in the participants ability to cope. In sessions 4 and 8, participants are asked how they feel about their trauma. With this exception, participants direct the sessions.
Study: NCT03630289

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB)
Description: Surgical tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients.
Study: NCT01870206

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent OPV Birmex
Description: Newborns who receive OPV vaccine produced in Vero cells by Birmex one dose of vaccine immediately after random allocation (at birth). A second dose is given four weeks after the first application.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent OPV Sanofi Pasteur
Description: Newborns who receive OPV vaccine produced in Vero cells by Sanofi Pasteur one dose of vaccine immediately after random allocation (at birth). A second dose is given four weeks after the first application.
Study: NCT00976183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat will start at 200 mg QD on weeks 1 and 3, and escalating to 300 mg QD after safety has been evaluated following 2 cycles of treatment. If safety is acceptable, then the following patients could be treated at 400 mg QD on weeks 1 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat will be given as a lead-in dose escalation starting at 200 mg QD.
Study: NCT04340895

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Faecal Calprotectin Home Test
Description: A non-invasive, in vitro diagnostic test for the determination of FC levels in human stool samples in combination with the dedicated 'CalproSmart' smartphone application.~This test helps participants to self-monitor their FC levels at their own homes, ensuring an adequate and effective medical treatment regimen performed by the investigator.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRO-2 Scoring
Description: Monitoring of clinical symptoms will be performed by PRO-2 scoring, which includes rectal bleeding (RB) and stool frequency (SF) assessment obtained within the last 3-days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PRO-2 Scoring
Description: Monitoring of clinical symptoms will be performed by PRO-2 scoring, which includes rectal bleeding (RB) and stool frequency (SF) assessment obtained within the last 3-days.
Study: NCT02814916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Description: Dalbavancin was administered intravenously over 30 (± 5) minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Description: Dalbavancin was administered intravenously over 30 (± 5) minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin was administered intravenously over 60 (± 10) minutes every 6 (± 1) hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxacillin
Description: Oxacillin was administered intravenously over 60 (± 10) minutes every 6 (± 1) hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flucloxacillin
Description: Flucloxacillin was administered intravenously over 60 (± 10) minutes every 6 (± 1) hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefadroxil
Description: Cefadroxil was administered orally every 12 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Clindamycin was administered orally every 8 hours.
Study: NCT03058029

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelesis200
Description: Subject would take Gelesis200 capsules 2 times per day.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject would take placebo capsules 2 times per day.
Study: NCT04644224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Activity
Description: Attend health coaching session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Activity
Description: Attend health coaching session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Attend resource navigation session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Attend resource navigation session

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive handbook

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Support Group Therapy
Description: Attend support group

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Support Group Therapy
Description: Attend support group
Study: NCT03583099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COPD plus CAPTURE education and patient-level information
Description: Basic COPD Education plus CAPTURE education and patient-level CAPTURE information will be provided to all practice personnel randomized to the 'CAPTURE + COPD Education' arm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: COPD Education Only
Description: Practice clinicians will receive basic COPD education only. Patient-level CAPTURE information will not be provided.
Study: NCT04587518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personality-Based Cognitive Behavioral Therapy
Description: The study treatment will take place across 18-sessions. The first session will involve psychoeducation regarding BPD.The next two sessions with include exercises drawn from Behavioral Activation (i.e., identification of value-based goals) and Motivational Interviewing (i.e., pros and cons \[long and short-term consequences\] of tolerating emotions, engaging in prosocial behavior, and delaying gratification). Next, patients will receive 5 sessions of cognitive interventions (i.e., cognitive reappraisal related to situations/emotions, schema related to relationships, 5 sessions of behavior change skills (i.e., acting opposite to emotion-driven urges, exposure, assertiveness training), and 5 sessions of mindfulness skills (i.e., nonjudgmental emotion awareness, compassion training, urge surfing). Finally, treatment will conclude with 2 sessions of Relapse Prevention strategies. All sessions will last for 60 minutes in duration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personality-Based Cognitive Behavioral Therapy
Description: The study treatment will take place across 18-sessions. The first session will involve psychoeducation regarding BPD.The next two sessions with include exercises drawn from Behavioral Activation (i.e., identification of value-based goals) and Motivational Interviewing (i.e., pros and cons \[long and short-term consequences\] of tolerating emotions, engaging in prosocial behavior, and delaying gratification). Next, patients will receive 5 sessions of cognitive interventions (i.e., cognitive reappraisal related to situations/emotions, schema related to relationships, 5 sessions of behavior change skills (i.e., acting opposite to emotion-driven urges, exposure, assertiveness training), and 5 sessions of mindfulness skills (i.e., nonjudgmental emotion awareness, compassion training, urge surfing). Finally, treatment will conclude with 2 sessions of Relapse Prevention strategies. All sessions will last for 60 minutes in duration.
Study: NCT04776083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: first line systemic therapy
Description: first line systemic therapy according to the genetic mutation 0f the patient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: first line systemic therapy
Description: first line systemic therapy according to the genetic mutation 0f the patient

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D radiotherapy or IMRT
Description: Hypo-fractionated radiotherapy to the primary lesion
Study: NCT04019379

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Phosphorus Diet
Description: Controlled research diet of high phosphorus (with low calcium)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Phosphorus Diet
Description: Controlled research diet of high phosphorus (with low calcium)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Phosphorus Diet
Description: Controlled research diet of low phosphorus (with low calcium)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Phosphorus Diet
Description: Controlled research diet of low phosphorus (with low calcium)
Study: NCT04750824

Intervention type: DRUG
Intervention: Afatinib
Description: Afatinib

Intervention type: DRUG
Intervention: other systemic therapy
Description: other systemic therapy
Study: NCT04557410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PolyMVA
Description: One-half teaspoon of PolyMVA contains the following:~* Daily Value Thiamin (B-1) 23mg 1,533 Riboflavin (B-2) 0.45mg 26 Vitamin B-12 460mcg 7,666 Proprietary Blend 32mg - contains the following ingredients (no FDA value has been established on any of the following): Palladium, Alpha Lipoic Acid, Molybdenum, Rhodium, Ruthenium, Formyl Methionine, N-acetyl Cysteine.~For each ml of Poly-MVA, the exact dosages are as follows:~Palladium: 3.97mg Molybdenum: 0.044mg Ruthenium: 0.0014mg Rhodium: 0.014mg Lipoic Acid: 7.68mg Thiamine (B1): 9.26mg Riboflavin (B2): 0.174mg B12: 0.185mg Formyl Methionine: 0.026mg N-Acetyl cysteine: 0.185mg Vitamin A acetate 100 IU~Other Ingredients: Distilled water, purified water, thiamine hydrochloride, Vitamin B12 as cyanocobalamin.